Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
PaperCitations, authors & open-access status
CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 282 citations, 2021 year and bronze oa status.
282
Citations
2021
Year
bronze
OA Status